Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors
(CARs) has shown promise, particularly for the treatment of hematological malignancies. To …

In haploidentical stem cell transplantations (haplo-SCT), nearly all patients have more than
one donor. A key issue in the haplo-SCT setting is the search for the best donor, because …

BACKGROUND. Graft-versus-host disease (GVHD) is a major cause of morbidity and
mortality following allogeneic hematopoietic stem cell transplantation (HCT). In mice, naive T …

Conventional intratumoural drug delivery systems often struggle to achieve both high
permeability and long-term retention. Smaller nanoparticles (NPs) readily diffuse into deep …

Recovery of immunity is delayed in recipients of T-depleted grafts. Adoptive transfer of
memory T-cells may improve immune response to common pathogens. A cohort of 53 …

Since the first allogeneic hematopoietic stem cell transplantation (HCT) was performed by
Dr. E. Donnall Thomas in 1957, the field has advanced with new stem cell sources, immune …

T-cell depletion of an HLA-haploidentical (haplo) graft is often used to reduce the risk of graft-
versus-host disease (GVHD), but the lack of donor T cells in the infused product may lead to …

Background T‐cell depletion (TCD) effectively reduces severe graft‐versus‐host disease in
recipients of HLA‐mismatched allografts. However, TCD is associated with delayed immune …

Abstract αβT-cell-depleted allogeneic hematopoietic cell transplantation holds promise for
the safe and accessible therapy of both malignant and non-malignant blood disorders. Here …

Promising results have been reported for adult patients with high-risk hematologic
malignancies undergoing haploidentical bone marrow transplant (haploBMT) with …